Google Joins AbbVie in $1.5 Billion Aging Disease Effort

AbbVie Inc. (ABBV), the drugmaker spun off from Abbott Laboratories last year, and Google Inc. (GOOG)’s Calico will spend as much as $1.5 billion to tackle age-related diseases, including cancer and neurodegenerative disorders.

Calico will be responsible for research and development, including the creation of a facility in the San Francisco Bay Area, and AbbVie will handle late-stage trials and commercialization activities, the companies said today in a statement. Both companies initially will provide $250 million each, with the potential to add $500 million each.

AbbVie’s “broad R&D experience and capabilities will complement Calico’s biotechnology expertise and innovative scientific approaches,” Michael Severino, AbbVie’s chief scientific officer, said in the statement.

Calico, a life-sciences company created last September by Google to focus on aging and associated diseases, is headed by Art Levinson, who is chairman of Roche Holding AG’s Genentech biotechnology unit and Apple Inc. (AAPL) The company was founded as Mountain View, California-based Google stepped up investments in areas outside its core online-advertising and consumer-services business.

In announcing Calico’s creation, Google CEO Larry Page said in a blog post that the company hoped to improve “millions of lives” with “longer term, moonshot thinking around health care and biotechnology.”

AbbVie, based in North Chicago, Illinois, has been adding to its portfolio since spinning off from Abbott. It will move its tax address outside the U.S. after completing a $55 billion purchase of Shire Plc, and today announced a $275 million agreement to develop Infinity Pharmaceutical Inc.’s duvelisib, an experimental cancer treatment.

“Our goal is to make progress on a very basic challenge: how to help people stay healthier for longer,” Levinson wrote in a blog post today. The collaboration with AbbVie will “turbocharge our efforts,” he said.

To contact the reporter on this story: Caroline Chen in New York at cchen509@bloomberg.net

To contact the editors responsible for this story: Reg Gale at rgale5@bloomberg.net Andrew Pollack, Angela Zimm

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.